Improving the postmarket surveillance of total joint arthroplasty devices

Open Rheumatology Journal

Volumn 2, Issue , 2008, Pages 7-12

  Mahomed, Nizar N ^a,d   Syed, Khalid ^a   Sledge, Clement B ^b   Brennan, Troyen A ^b   Liang, Matthew H ^b,c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Boston VA Health Care System   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOCOMPATIBILITY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HIP ARTHROPLASTY; HUMAN; JOINT DISLOCATION; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; SCORING SYSTEM; UNITED STATES;

EID: 85056039140     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312900802010007     Document Type: Article

References (23)

1. Harris WH, Sledge CB. Total hip and total knee replacement (2). N Engl J Med 1990; 323(12): 801-07.
2. Thornhill, TS. Mechanisms of Failure of Total Hip Arthroplasty in Revision Total Hip Arthroplasty. Bono JV, McCarthy JC, Thornhill TS, Bierbaum BE, Turner RH. Springer, 1999. NY, p 1-3.
3. Bono JV, Sanford L, Toussaint JT. Severe polyetheylene wear in total hip arthroplasty: Observations from retrieved AML plus hip implants with an ACS polyethylene liner. J Arthroplasty 1994; 9: 119-25..
4. Udomkiat P, Dorr LD, Wan Z. Cementless hemispheric porous-coated sockets implanted with press-fit technique without screws: Average ten-year followup. J Bone Joint Surg 2002; 84: 1195-200.
5. B Kermode-Scott. Agencies "failed miserably" over COX-2 inhibitor. BMJ 2005; 330: 113.
6. Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351(17): 1707-9.
7. Hampton T. Experts point to lessons learned from controversy over rofecoxib safety. JAMA 2005; 293(4): 413-4.
8. Baron JA, Barrett J, Katz JN, Liang MH. Total hip arthroplasty: use and select complications in the US Medicare population. Am J Public Health 1996; 86: 70-2.
9. Mahomed N, Katz JN. Revision total hip arthroplasty. Indications and outcomes. Arthritis Rheumatism 1996; 39: 1939-50.
10. National Hospital Discharge Survey: National Bureau of Health Statistics; 1993.
11. Merrill RA. Regulation of drugs and devices: an evolution. Health Affairs 1994; 13: 47-69.
12. Kessler DA, Pape SM, Sundwall DN. The federal regulation of medical devices. New Eng J Med 1987; 317: 357-66.
13. Kessler DA. Hastings lecture, December 10, 1993, Rockville, Maryland, Artificial Organs 1994; 18: 718-24.
14. Solomon RP, Koch FA. The new implant tracking regulations. Defining, implementing, documenting. AORN J 1993; 58: 1142-51.
15. Castro FP, Chimento G, Munn BG, Levy RS, Timon S, Barrack RL. An analysis of food and drug administration medical device reports relating to total joint components. J Arthroplasty 1997; 12: 765-71.
16. Murray DW, Carr AJ, Bulstrode CJ. Which primary total hip replacement? J Bone Joint Surg (Br) 1995; 77: 520-27.
17. Gross M. A critique of the methodologies used in clinical studies of hip joint arthroplasty published in the english language orthopedic literature. J Bone Joint Surg (Am) 1988; 70: 1364-71.
18. Gartland JJ. Orthopedic clinical research. Deficiencies in experimental design and determinations of outcome. J Bone Joint Surg (Am) 1988; 70: 1357-64.
19. Burlington DB. FDA CDRH Annual Report Fiscal Year 1998. Rockville, MD: Center for Devices and Radiological Health FDA; 1998.
20. Marwick C. Concern expressed about FDA reform legislation. JAMA 1997; 278: 459.
21. Access to therapeutic products: The regulatory process in Canada. Health Canada, 2006.
22. Malchau H, Herberts P, Ahnfelt L. Prognosis of total hip replacement in Sweden: follow-up of 92,675 operations performed 1978-1990. Acta Orthop Scand 1993;64: 497-506.
23. Malenka DJ, Kaplan AV, Sharp SM, Wennberg JE. Postmarketing surveillance of medical devices using medicare claims. Health Affairs 2005; 24: 928-38.